Yang MH, Chen CL, Chau GY, Chiou SH, Su CW, Chou TY, Peng WL, Wu

Yang MH, Chen CL, Chau GY, Chiou SH, Su CW, Chou TY, Peng WL, Wu JC: Comprehensive analysis of the independent effect of twist and snail in promoting metastasis of hepatocellular carcinoma. Hepatology 2009, 50:1464–74.PubMedCrossRef 30. Zhang A, Chen G, Meng L, Wang Q, Hu W, Xi L, Gao Q, Wang S, Zhou J, Xu G, Meng L, Ma D: Antisense-Snail transfer inhibits tumor metastasis by inducing E-cadherin expression. Anticancer Res 2008, 28:621–8.PubMed 31. Berx G, Becker KF, Hofler H, van Roy F: Mutations of the human E-cadherin (CDH1) gene. Hum Mutat 2008, 12:226–237.CrossRef 32. Savagner P, Yamada KM, Thiery JP: The zinc-finger protein

slug causes desmosome dissociation, an initial and Lenvatinib clinical trial necessary step for growth factor-induced epithelial-mesenchymal transition. J Cell Biol 1997, 137:1403–1419.PubMedCrossRef 33. Thiery JP: Epithelial-mesenchymal transitions in tumor progression. Nat Rev Cancer 2002, 2:442–454.PubMedCrossRef 34. Kanai

Y, Ushijima S, Tsuda H, Sakamoto M, Hirohashi S: Aberrant DNA methylation precedes loss of heterozygosity on chromosome 16 in chronic hepatitis and liver cirrhosis. Cancer Lett 2000, 148:73–80.PubMedCrossRef 35. Berx G, Cleton-Jansen AM, Nollet F, de Leeuw WJ, van de Vijver M, Cornelisse C, van Roy F: E-Cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. EMBO J 1995, 14:6107–6115.PubMed 36. Guilford P, Hopkins J, Harraway J, McLeod M, McLeod N, Harawira P, Taite H, Scoular R, Miller A, Reeve AE: E-Cadherin germline mutations in familial gastric cancer. Nature caspase inhibitor (Lond.) 1998, 392:402–405.CrossRef Adenosine triphosphate 37. Risinger JI, Berchuck A, Kohler MF, Boyd J: Mutations of the E-cadherin gene in human gynecologic cancers. Nat Genet

1994, 7:98–102.PubMedCrossRef 38. Doyle S, Evans AJ, Rakha EA, Green AR, Ellis IO: Influence of E-cadherin expression on the mammographic appearance of invasive nonlobular breast carcinoma detected at screening. Radiology 2009, 253:51–5.PubMedCrossRef 39. Sarrió D, Palacios J, Hergueta-Redondo M, Gómez-López G, Cano A, Moreno-Bueno G: Functional characterization of E- and P-cadherin in invasive breast cancer cells. BMC Cancer 2009, 9:74.PubMedCrossRef 40. Ihara A, Koizumi H, Hashizume R, Uchikoshi T: Expression of epithelial cadherin and α- and β-catenins in nontumoral livers and hepatocellular carcinomas. Hepatology 1996, 23:1441–1447.PubMed 41. Wei Y, Van Nhieu JT, Prigent S, Srivatanakul P, CP-690550 Tiollais P, Buendia MA: Altered expression of E-cadherin in hepatocellular carcinoma: correlations with genetic alterations, β-catenin expression, and clinical features. Hepatology 2002, 36:692–701.PubMedCrossRef 42. Endo K, Ueda T, Ueyama J, Ohta T, Terada T: Immunoreactive E-cadherin, α-catenin, β-catenin, and γ-catenin proteins in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, and patients’ survival. Hum Pathol 2000, 31:558–565.PubMedCrossRef 43.

Comments are closed.